Peptide Synthesis Market worth $1.54 billion by 2031 - Exclusive Report by MarketsandMarkets™

The peptide synthesis market is forecast to grow from USD 0.98B in 2026 to USD 1.54B by 2031, implying a 9.5% CAGR, supported by rising peptide therapeutics R&D and higher adoption of automated, high-throughput synthesis workflows. The services segment is projected to lead growth at 12.0% CAGR, while reagents & consumables remain the largest product-type share (71.4% in 2025). Recent capacity-expansion and consolidation moves—such as Samsung Biologics’ proposed USD 1.83B acquisition of PolyPeptide and Bachem’s USD 625M+ investment in its Sisslerfeld facility—signal continued investment and vertical integration as demand for complex/modified peptides increases.

Analysis

The important signal is not the market size; it is the mix shift toward recurring consumables and outsourced synthesis. That favors scaled, process-heavy platforms with installed base leverage and high utilization economics, while pure instrument vendors see a much weaker incremental benefit because peptide demand is still a small slice of their total revenue.

Competitive dynamics should skew toward companies that can offer end-to-end workflows and capacity, not just reagents. Over the next 1-3 quarters, any earnings upside is more likely to show up in utilization, backlog, and margin mix at peptide CDMOs and specialty suppliers than in broad life-science tools names; over 6-18 months, consolidation should raise the strategic value of scarce peptide manufacturing assets. The flip side is that faster biological synthesis adoption could gradually commoditize some chemical synthesis inputs, putting pressure on lower-value reagent suppliers and smaller standalone synthesis shops.

The contrarian point is that consensus may be overestimating how much this helps the large diversified names. For TMO and DHR, the theme is supportive but not thesis-changing; the market is too small to move group revenue meaningfully unless peptide outsourcing accelerates sharply or becomes a larger share of biopharma R&D budgets. The more tradable angle is valuation support for niche peptide producers, especially if M&A continues to validate scarcity value and capacity remains tight.

Key Decisions for Investors

• Overweight BCHMF on a 6-12 month view; use any 5-7% pullback to build. Thesis: capacity expansion + consolidation should support a scarcity premium, with 15-20% upside if execution stays on track; falsify if capex overruns or customer demand slips in the next two quarters.
• Keep TMO and DHR at neutral weights rather than adding exposure. The theme is additive to consumables and QC, but not large enough to justify multiple expansion by itself; re-evaluate only if life-science organic growth inflects by >100 bps for two consecutive quarters.
• If seeking a cleaner expression, consider a small basket long BCHMF / MKKGY and flat TMO/DHR for 3-6 months. This isolates peptide-specific monetization and reduces dilution from broader lab-tools cyclicality; risk is that M&A enthusiasm fades and the basket underperforms on valuation compression.
• Do not chase MLAB or generic instrumentation names on this report alone. Wait for hard evidence of peptide-related order acceleration or segment disclosure before taking risk; otherwise the catalyst is too diffuse to trade.
• Set an alert on any additional CDMO or peptide-platform deal announcement over the next 1-3 months. A second transaction would likely confirm a consolidation premium and would be the best trigger to add to the niche peptide complex.